Skip to main content Skip to footer

Orexo press releases

Notice of Annual General Meeting of Orexo

8 March 2011 at 08:00 – Regulatory – General Meeting

Notice of Annual General Meeting of Orexo

Abstral® approved in Canada

22 February 2011 at 14:30 – Regulatory

Abstral® approved in Canada

Report from Orexo AB’s extraordinary shareholders’ meeting, 16 February 2011

17 February 2011 at 07:00 – Regulatory – General Meeting

Report from Orexo AB’s extraordinary shareholders’ meeting, 16 February 2011

Orexo AB (publ.) - Year-end Report, January to December 2010

16 February 2011 at 08:00 – Regulatory – Report – Q4

Orexo AB (publ.) - Year-end Report, January to December 2010

Anders Lundström to be the new CEO of Orexo

13 January 2011 at 08:00 – Regulatory

Anders Lundström to be the new CEO of Orexo

Notice of Extraordinary General Meeting of Orexo AB, February 16, 2011

11 January 2011 at 12:00 – Regulatory – General Meeting

Notice of Extraordinary General Meeting of Orexo AB, February 16, 2011

Orexo AB (publ.) – Interim report, January-September 2010

10 November 2010 at 08:00 – Regulatory – Report – Q3

Orexo AB (publ.) – Interim report, January-September 2010

Update on the FDA review for Abstral™

7 September 2010 at 08:15 – Regulatory

Update on the FDA review for Abstral™

Orexo notes significant change in its owner structure

26 August 2010 at 17:30 – Regulatory

Orexo notes significant change in its owner structure

Orexo AB (publ.) – Interim report, January-June 2010

20 August 2010 at 08:01 – Regulatory – Report – Q2

Orexo AB (publ.) – Interim report, January-June 2010

Orexo confirms Abstral PDUFA date update

2 June 2010 at 13:30 – Regulatory

Orexo confirms Abstral PDUFA date update

Orexo reports continued strong AbstralTM sales in Europe

18 May 2010 at 08:15 – Regulatory

Orexo reports continued strong AbstralTM sales in Europe

President and CEO

Nikolaj Sørensen

EVP & Chief Financial Officer

Fredrik Järrsten